Left-Sided MRSA Endocarditis Successfully Treated with a Combination of Daptomycin and Ceftaroline
| Autor: | Claudia D. Jarrin Tejada, Richard P. Wenzel |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty business.industry Mortality rate biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease_cause medicine.disease Left sided Infectious Diseases Bacterial endocarditis Staphylococcus aureus Internal medicine medicine Vancomycin Endocarditis MRSA bacteremia Daptomycin business medicine.drug |
| Zdroj: | Clinical Microbiology Newsletter. 37:58-59 |
| ISSN: | 0196-4399 |
| DOI: | 10.1016/j.clinmicnews.2015.03.002 |
| Popis: | Vancomycin is the recommended drug for treating endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA). Daptomycin is not inferior to vancomycin for treating MRSA bacteremia and right-sided endocarditis. There is synergistic activity between daptomycin and ceftaroline. Fifty percent of all cases of bacterial endocarditis are caused by S. aureus, half of which are caused by methicillin-resistant strains (1). A retrospective review of 133 cases of S. aureus endocarditis indicated an overall mortality rate of 38% for left-sided endocarditis in comparison to 17% for right-sided endocarditis (2). Since data on left-sided S. aureus endocarditis are limited, optimal therapy remains undefined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect